O	0	5	Phase
O	6	9	III
O	10	17	placebo
O	17	18	-
O	18	28	controlled
O	28	29	,
O	30	36	double
O	36	37	-
O	37	42	blind
O	42	43	,
O	44	54	randomized
O	55	60	trial
O	61	63	of
B-intervention	64	77	pegfilgrastim
O	78	80	to
O	81	87	reduce
O	88	91	the
O	92	96	risk
O	97	99	of
B-condition	100	107	febrile
I-condition	108	119	neutropenia
O	120	122	in
B-eligibility	123	129	breast
I-eligibility	130	136	cancer
I-eligibility	137	145	patients
I-eligibility	146	155	receiving
I-eligibility	156	165	docetaxel
I-eligibility	165	166	/
I-eligibility	166	182	cyclophosphamide
I-eligibility	183	195	chemotherapy
O	195	196	.

O	197	210	Pegfilgrastim
O	211	213	is
O	214	215	a
O	216	225	pegylated
O	226	230	form
O	231	233	of
O	234	244	filgrastim
O	244	245	,
O	246	247	a
O	248	259	recombinant
O	260	267	protein
O	268	270	of
O	271	282	granulocyte
O	283	289	colony
O	289	290	-
O	290	301	stimulating
O	302	308	factor
O	308	309	,
O	310	314	that
O	315	317	is
O	318	322	used
O	323	325	to
O	326	332	reduce
O	333	336	the
O	337	341	risk
O	342	344	of
O	345	352	febrile
O	353	364	neutropenia
O	365	366	(
O	366	368	FN
O	368	369	)
O	369	370	.

O	371	375	Here
O	375	376	,
O	377	379	we
O	380	386	report
O	387	390	the
O	391	398	results
O	399	401	of
O	402	403	a
O	404	409	phase
O	410	413	III
O	414	419	trial
O	420	422	of
O	423	436	pegfilgrastim
O	437	439	in
O	440	446	breast
O	447	453	cancer
O	454	462	patients
O	463	472	receiving
O	473	482	docetaxel
O	483	486	and
O	487	503	cyclophosphamide
O	504	505	(
O	505	507	TC
O	507	508	)
O	509	521	chemotherapy
O	521	522	.

O	523	525	We
O	526	535	conducted
O	536	537	a
O	538	544	double
O	544	545	-
O	545	550	blind
O	550	551	,
O	552	559	placebo
O	559	560	-
O	560	570	controlled
O	570	571	,
O	572	582	randomized
O	583	588	trial
O	589	591	to
O	592	601	determine
O	602	605	the
O	606	614	efficacy
O	615	617	of
O	618	631	pegfilgrastim
O	632	634	in
O	635	643	reducing
O	644	647	the
O	648	652	risk
O	653	655	of
O	656	658	FN
O	659	661	in
O	662	667	early
O	667	668	-
O	668	673	stage
O	674	680	breast
O	681	687	cancer
O	688	696	patients
O	696	697	.

O	698	699	A
O	700	705	total
O	706	708	of
B-total-participants	709	712	351
O	713	718	women
O	719	720	(
B-intervention-participants	720	723	177
O	724	726	in
O	727	730	the
O	731	744	pegfilgrastim
O	745	750	group
O	751	754	and
B-control-participants	755	758	174
O	759	761	in
O	762	765	the
B-control	766	773	placebo
O	774	779	group
O	779	780	)
B-age	781	788	between
I-age	789	791	20
I-age	792	795	and
I-age	796	798	69
I-age	799	804	years
O	805	807	of
O	808	811	age
O	812	816	with
O	817	822	stage
O	823	824	I
O	824	825	-
O	825	828	III
O	829	837	invasive
O	838	844	breast
O	845	854	carcinoma
O	855	858	who
O	859	863	were
O	864	866	to
O	867	874	receive
O	875	877	TC
O	878	890	chemotherapy
O	891	892	(
O	892	901	docetaxel
O	902	904	75
O	905	907	mg
O	907	908	/
O	908	909	m
O	909	910	(
O	910	911	2
O	911	912	)
O	913	916	and
O	917	933	cyclophosphamide
O	934	937	600
O	938	940	mg
O	940	941	/
O	941	942	m
O	942	943	(
O	943	944	2
O	944	945	)
O	946	951	every
O	952	953	3
O	954	959	weeks
O	959	960	)
O	961	963	as
O	964	970	either
O	971	982	neoadjuvant
O	983	985	or
O	986	994	adjuvant
O	995	1002	therapy
O	1003	1007	were
O	1008	1016	enrolled
O	1016	1017	;
B-total-participants	1018	1021	346
O	1022	1024	of
O	1025	1030	these
O	1031	1039	patients
O	1040	1044	were
O	1045	1052	treated
O	1053	1057	with
O	1058	1064	either
O	1065	1078	pegfilgrastim
O	1079	1080	(
O	1080	1081	n
O	1082	1083	=
B-intervention-participants	1084	1087	173
O	1087	1088	)
O	1089	1091	or
O	1092	1099	placebo
O	1100	1101	(
O	1101	1102	n
O	1103	1104	=
B-control-participants	1105	1108	173
O	1108	1109	)
O	1109	1110	.

O	1111	1114	The
B-outcome	1115	1124	incidence
I-outcome	1125	1127	of
I-outcome	1128	1130	FN
O	1131	1134	was
O	1135	1148	significantly
O	1149	1154	lower
O	1155	1157	in
O	1158	1161	the
O	1162	1175	pegfilgrastim
O	1176	1181	group
O	1182	1186	than
O	1187	1189	in
O	1190	1193	the
O	1194	1201	placebo
O	1202	1207	group
O	1208	1209	(
B-iv-bin-percent	1209	1210	1
I-iv-bin-percent	1210	1211	.
I-iv-bin-percent	1211	1212	2
O	1213	1215	vs
O	1215	1216	.
B-cv-bin-percent	1217	1219	68
I-cv-bin-percent	1219	1220	.
I-cv-bin-percent	1220	1221	8
I-cv-bin-percent	1222	1223	%
O	1223	1224	,
O	1225	1237	respectively
O	1237	1238	;
O	1239	1240	P
O	1241	1242	<
O	1243	1244	0
O	1244	1245	.
O	1245	1248	001
O	1248	1249	)
O	1249	1250	.

O	1251	1253	In
O	1254	1262	addition
O	1262	1263	,
O	1264	1272	patients
O	1273	1275	in
O	1276	1279	the
O	1280	1293	pegfilgrastim
O	1294	1299	group
O	1300	1308	required
O	1309	1313	less
B-outcome	1314	1329	hospitalization
I-outcome	1330	1333	and
I-outcome	1334	1345	antibiotics
I-outcome	1346	1349	for
I-outcome	1350	1352	FN
O	1352	1353	.

O	1354	1358	Most
B-outcome	1359	1366	adverse
I-outcome	1367	1373	events
O	1374	1378	were
O	1379	1389	consistent
O	1390	1394	with
O	1395	1400	those
O	1401	1409	expected
O	1410	1413	for
O	1414	1420	breast
O	1421	1427	cancer
O	1428	1436	subjects
O	1437	1446	receiving
O	1447	1449	TC
O	1450	1462	chemotherapy
O	1462	1463	.

O	1464	1477	Pegfilgrastim
O	1478	1480	is
O	1481	1485	safe
O	1486	1489	and
O	1490	1503	significantly
O	1504	1511	reduces
O	1512	1515	the
O	1516	1525	incidence
O	1526	1528	of
O	1529	1531	FN
O	1532	1534	in
O	1535	1541	breast
O	1542	1548	cancer
O	1549	1557	patients
O	1557	1558	.
